A systematic review 1 including 13 RCTs with a total of 1,655 subjects was abstracted in DARE. All trials favoured lansoprazole over the histamine-2-receptor antagonists. At 4 weeks, the risk ratio for ulcer healing was 1.33 (95% CI 1.19 to 1.49) for all trials, and 1.23 (95% CI 1.09 to 1.39) for the 6 trials of higher methodological quality. For ulcer healing at 8 weeks the risk ratio was 1.12 (95% CI 1.06 to 1.19) for all trials, and 1.08 (95% CI 1.01 to 1.16) for the 6 trials with higher methodological quality.
Primary/Secondary Keywords